Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282355 · ClinicalTrials.gov registry record · NA
Astaxanthin Reduces Exercising Heart Rate.
A NA study, sponsored by University of North Alabama.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT05282355: Completed NA study, sponsored by University of North Alabama.
NCT05282355 is a NA study that has completed, run by University of North Alabama. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05282355, a NA study, has completed, sponsored by University of North Alabama.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
Briefly, this study involved 2 trials: baseline (Trial 1) and post-astaxanthin intervention (Trial 2). Both trials included participants completing a graded exercise test while connected to a metabolic cart, to measure cardiorespiratory measures. Between trials, participants were supplemented with either 12 mg of astaxanthin or placebo for 4 weeks. It was hypothesized astaxanthin supplementation would increase rates of fat oxidation, while decreasing carbohydrate oxidation and blood lactate accumulation.
Primary Outcome
Substrate oxidation rates reflect cellular utilization of carbohydrates and lipids at rest and during exercise. If changes exist from astaxanthin supplementation, they would manifest themselves likely via increases to rates of fat oxidation at all stages and a subsequent decrease in carbohydrate oxidation rates at each stage.
Interventions
- DIETARY_SUPPLEMENT Astaxanthin
- DIETARY_SUPPLEMENT Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2021-07-02 |
| Phase | NA |
What the finished NCT05282355 record still lists
NCT05282355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Astaxanthin is the first listed.
NCT05282355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05282355 about?
NCT05282355 is a clinical study titled "Astaxanthin Reduces Exercising Heart Rate.". Briefly, this study involved 2 trials: baseline (Trial 1) and post-astaxanthin intervention (Trial 2). Both trials included participants completing a graded exercise test while connected to a metabolic cart, to measure cardiorespiratory measures. Between trials, participants were supplemented with e...
What is the current status of trial NCT05282355?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2021-05-12. Estimated completion is 2021-07-02.
What interventions are being tested in trial NCT05282355?
The interventions under investigation include: Astaxanthin (DIETARY_SUPPLEMENT), Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05282355?
This trial is sponsored by University of North Alabama, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05282355's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI